Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., & Kapiteijn, E. (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040–1051. https://doi.org/10.1038/s41416-022-02133-6

Kenchappa, R. S., Liu, Y., Argenziano, M. G., Banu, M. A., Mladek, A. C., West, R., Luu, A., Quiñones-Hinojosa, A., Hambardzumyan, D., Justilien, V., Leitges, M., Sarkaria, J. N., Sims, P. A., Canoll, P., Murray, N. R., Fields, A. P., & Rosenfeld, S. S. (2021). Protein kinase Cι and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Reports, 37(8), 110054. https://doi.org/10.1016/j.celrep.2021.110054